Literature DB >> 19154463

Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas.

Christian Bolenz1, Michael Gierth, Rainer Grobholz, Thomas Köpke, Axel Semjonow, Christel Weiss, Peter Alken, Maurice Stephan Michel, Lutz Trojan.   

Abstract

OBJECTIVE: To describe the localization and to assess the clinical implications of areas of undetected prostate cancer in radical prostatectomy (RP) specimens, focusing on patients with unilaterally negative preoperative biopsy cores. PATIENTS AND METHODS: The study included 149 of 559 consecutive patients (26.7%) who had RP for prostate cancer. Unilateral prostate cancer was diagnosed from prostate biopsies, taken by several physicians, but > or = pT2c disease was present in the RP specimen. The prostate was dissected by standardized transversal cuts and tumour areas were mapped by one genitourinary pathologist. To estimate the tumour size and location, areas of prostate cancer were transferred to a digital grid database representing the prostate by 794 units.
RESULTS: The most frequent location of undetected prostate cancer was in the dorsalateral region and in the apex of the prostate. The mean tumour volume of the false-negative lobe was significantly lower than contralaterally (18.9 vs 47.5 units, P < 0.001). In 36 of 149 patients (24.2%), the tumour volume on the negative biopsy side was equal or higher than on the positive biopsy side; in the final RP specimen, 60 patients (40.3%) had capsular involvement on the negative biopsy side.
CONCLUSION: Significantly many patients with newly diagnosed prostate cancer remain clinically understaged. The apical and dorsolateral region of the prostate are not adequately represented in current biopsy strategies. Undetected tumour areas are often clinically significant by size and capsular involvement, indicating a direct clinical implication when planning nerve-sparing RP or focal therapy. Our results show a continuing need for optimized and standardized biopsy protocols.

Entities:  

Mesh:

Year:  2009        PMID: 19154463     DOI: 10.1111/j.1464-410X.2008.08243.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Authors:  Joan Alexander; Jude Kendall; Jean McIndoo; Linda Rodgers; Robert Aboukhalil; Dan Levy; Asya Stepansky; Guoli Sun; Lubomir Chobardjiev; Michael Riggs; Hilary Cox; Inessa Hakker; Dawid G Nowak; Juliana Laze; Elton Llukani; Abhishek Srivastava; Siobhan Gruschow; Shalini S Yadav; Brian Robinson; Gurinder Atwal; Lloyd C Trotman; Herbert Lepor; James Hicks; Michael Wigler; Alexander Krasnitz
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

2.  Clinical impact of intraoperative frozen sections during nerve-sparing radical prostatectomy.

Authors:  Elmar Heinrich; Georg Schön; Frank Schiefelbein; Maurice Stephan Michel; Lutz Trojan
Journal:  World J Urol       Date:  2010-04-01       Impact factor: 4.226

3.  Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core Biopsy.

Authors:  Hiromoto Tei; Hideaki Miyake; Ken-Ichi Harada; Masato Fujisawa
Journal:  Curr Urol       Date:  2015-07-10

4.  Clinical map document based on XML (cMDX): document architecture with mapping feature for reporting and analysing prostate cancer in radical prostatectomy specimens.

Authors:  Okyaz Eminaga; Reemt Hinkelammert; Axel Semjonow; Joerg Neumann; Mahmoud Abbas; Thomas Koepke; Olaf Bettendorf; Elke Eltze; Martin Dugas
Journal:  BMC Med Inform Decis Mak       Date:  2010-11-15       Impact factor: 2.796

5.  Localization of higher grade tumor foci in potential candidates for active surveillance who opt for radical prostatectomy.

Authors:  Sung Kyu Hong; James A Eastham; Samson W Fine
Journal:  Prostate Int       Date:  2013-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.